A weight-loss jab which could be available on the NHS by the end of the year can also reduce the risk of a heart attack or stroke by 20% Although it is not yet clear when the drug could be approved for such use in the UK PMGallagher1 and BawdenTom
A weight-loss jab can reduce the risk of a heart attack or stroke by 20 per cent, according to “exciting” trial results.
Novo Nordisk has been reluctant to announce a date for when it will become available until it is confident it will be able to meet demand, despite patient groups hoping to get access to it by the end of the year. About four million people in England are expected to be eligible for the drug, also known as semaglutide, on the NHS when it launches.
However, Britons wanting access to the “gamechanging” drug will have a little longer to celebrate as Wegovy is still not available on the NHS despite being authorised by the UK’s medicines regulator in September 2021. It is not yet clear when the drug could be approved for such use in the UK and the company declined to comment on the issue.
“Therefore, we are very excited about the results from Select showing that semaglutide 2.4mg reduces the risk of cardiovascular events. Select is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Man who shed 20 stone can't get surgery to remove loose skin on NHSWayne Shepherd believed he would be able to have the excess skin removed following gastric sleeve surgery
Read more »
Wegovy weight loss drug also cuts risk of heart attack and stroke by 20 per cent, trial shows🔴 The Wegovy weight loss drug reduces the risk of heart attacks and strokes by a fifth for people with obesity, according to the results of a major trial
Read more »
20 celebrities who gave us a masterclass in shutting down body-shamersBehold, some of the most epic comebacks the internet has ever seen.
Read more »
20 celebrities who gave us a masterclass in shutting down body-shamersFrom Jessie J and Serena Williams and Nicola Coughlan to Florence Pugh, these are 20 times our favourite celebrities shut down body-shamers in the very best way.
Read more »
Woman tells of relief after paedophile bus driver is jailed 20 years after abuseBrave Naomi Gibson told police when she was assaulted by predator Craig Wallace aged just 11. But he went on to rape two youngsters before finally being convicted last week.
Read more »
Association between troponin level and medium-term mortality in 20 000 hospital patientsIntroduction Cardiac troponin (cTn) concentrations above the manufacturer recommended upper limit of normal (ULN) are frequently seen in hospital patients without a clinical presentation consistent with type 1 myocardial infarction, and the significance of this is uncertain. The aim of this study was to assess the relationship between medium-term mortality and cTn concentration in a large consecutive hospital population, regardless of whether there was a clinical indication for performing the test. Method This prospective observational study included 20 000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital, and in whom a hs-cTnI assay was measured, regardless of the original clinical indication. Mortality was obtained via NHS Digital. Results A total of 20 000 patients were included in the analysis and 18 282 of these (91.4%) did not have a clinical indication for cardiac troponin I (cTnI) testing. Overall, 2825 (14.1%) patients died at a median of 809 days. The mortality was significantly higher if the cTnI concentration was above the ULN (45.3% vs 12.3% p|0.001 log rank). Multivariable Cox analysis demonstrated that the log10 cTnI concentration was independently associated with mortality (HR 1.76 (95% CI 1.65 to 1.88)). Landmark analysis, excluding deaths within 30 days, showed the relationship between cTnI concentration and mortality persisted. Conclusion In a large, unselected hospital population, in 91.4% of whom there was no clinical indication for testing, cTnI concentration was independently associated with medium-term cardiovascular and non-cardiovascular mortality in the statistical model tested. No data are available. The nature of the data sharing agreement with NHS Digital prevents sharing of these data.
Read more »